Meloxicam and Trikafta drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Meloxicam (meloxicam) and Trikafta (elexacaftor, ivacaftor, tezacaftor; ivacaftor). Common drug interactions include hospitalisation among females and adverse event following immunisation among males.

The phase IV clinical study analyzes what interactions people have when they take Meloxicam and Trikafta. It is created by eHealthMe based on reports of 26 people who take the same drugs from the FDA, and is updated regularly.

What is Meloxicam?

Meloxicam has active ingredients of meloxicam. It is often used in arthritis. eHealthMe is studying from 68,016 Meloxicam users. Check the latest studies of Meloxicam.

What is Trikafta?

Trikafta has active ingredients of elexacaftor, ivacaftor, tezacaftor; ivacaftor. eHealthMe is studying from 11,852 Trikafta users. Check the latest studies of Trikafta.

On Jul, 12, 2026

26 people who take Meloxicam and Trikafta together, and have interactions are studied.

Meloxicam and Trikafta drug interactions.

What are the common drug interactions of Meloxicam and Trikafta, by gender? *:

female:

Hospitalisation
Vomiting
Cough
Abdominal pain
Diarrhoea
Back pain
Decreased appetite
Eating disorder
Fatigue (feeling of tiredness)
Nausea (feeling of having an urge to vomit)

male:

Adverse event following immunisation
Aphthous ulcer (mouth ulcer)
Oropharyngeal pain
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Nasopharyngitis (inflammation of the nasopharynx)
Productive cough
Asthenia (weakness)
Back injury
Procedural complication
Pyrexia (fever)

What are the common drug interactions of Meloxicam and Trikafta, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Hospitalisation
Vomiting
Abdominal pain
Cough
Diarrhoea
Nephrolithiasis (calculi in the kidneys)
Weight decreased

20-29:

Abdominal pain upper
Alanine aminotransferase increased
Aspartate aminotransferase increased
Diplopia (double vision)
Dizziness
Hallucination (an experience involving the perception of something not present)
Head injury
Kidney infection
Loss of consciousness
Mental impairment (a condition affecting the body, perhaps through sight or hearing loss, a mobility difficulty or a health condition)

30-39:

Back pain
Decreased appetite
Eating disorder
Nasopharyngitis (inflammation of the nasopharynx)
Nausea (feeling of having an urge to vomit)
Vomiting
Cough
Eye irritation
Fatigue (feeling of tiredness)
Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)

40-49:

Adverse event following immunisation
Aphthous ulcer (mouth ulcer)
Oropharyngeal pain
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Cystic fibrosis (disease of the secretary glands)
Asthenia (weakness)
Back injury
Procedural complication
Pyrexia (fever)
Rash papular (redness with papule)

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

Cystic Fibrosis (disease of the secretary glands): 17 people, 65.38%
Mycobacterium Avium Complex Infection: 5 people, 19.23%
Birth Control: 5 people, 19.23%
Diabetes: 3 people, 11.54%

* Approximation only. Some reports may have incomplete information.

Do you take Meloxicam and Trikafta?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously